Siemens Healthineers received clearance for its Dimension Exl High-Sensitivity Troponin I Assay used to diagnose acute myocardial infarction.
The investment bank gave Danaher a Neutral rating and a $148 price target on the firm's shares, while it gave Agilent an Overweight rating with an $83 price target.
The Hologic Aptima Combo 2 and the Cepheid Xpert CT/NG assays have now been cleared for use in throat and rectum samples.
GenMark Diagnostics received clearance for a third BCID panel that the firm said paves the way for a customizable approach to sepsis MDx.
The Life Sciences business grew 10 percent year over year, while the Diagnostics business inched up 1 percent.
An early user of a new Mycoplasma genitalium and antibiotic resistance test from SpeeDx that uses the Xpert cartridge shared some initial validation data.
The agency plans to evaluate newer RDTs in the future, and it is collaborating to bring molecular testing nearer to patients.
The study authors said that many cases of drug resistance remained undetected due to inaccurate tests, resulting in more deaths from incorrect treatment.
The firm's Life Sciences segment grew 10 percent year over year during the quarter while its Diagnostics segment was up 4 percent.
Researchers showed that the test had equivalent results to a lab-based assay and has the potential for a faster turnaround time.